Navigation Links
Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
Date:1/28/2009

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating the disease. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over Amgen/Wyeth/Takeda's Enbrel (etanercept), the market sales-leading agent.

The new report entitled Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity finds that an oral disease-modifying drug with a novel mechanism of action that is priced 20 percent lower than etanercept plus methotrexate would earn a 25 percent patient share in the United States and a 20 percent patient share in Europe, according to surveyed U.S. and European rheumatologists.

Decision Resources' proprietary clinical gold standard in 2008 for rheumatoid arthritis was Enbrel, most notably because of its superior efficacy in inhibiting/slowing structural damage progression at one and two years compared with other agents in the market. Following its approval for the indication, which is likely to occur in 2010, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi (golimumab) will earn Decision Resources' gold standard for rheumatoid arthritis in 2012. Although Simponi's overall efficacy, safety and tolerability do not match that of Enbrel, its advantages in delivery differentiate it from Enbrel.

"Simponi ranks higher than Enbrel on the measures of dosage formulation and dosage frequency," said Decision Resources Analyst Dancella Fernandes, Ph.D. "Simponi offers an alternative formulation and once-monthly dosing compared with Enbrel's once- to twice-weekly dosing. By differentiating itself with improved delivery features, Simponi separates itself in a market crowded with drugs boasting similar efficacy and safety profiles."

About the Report

Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                             Decision Resources, Inc.
    Christopher Comfort                            Elizabeth Marshall
    781-296-2597                                   781-296-2563
    ccomfort@dresources.com                        emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: